Basic tumor marker test package for women

Basic laboratory test package specialized for screening the main women’s tumor risk markers.

Tumor markers are produced by tumor cells. Our laboratory determines the concentration of proteins that may indicate some type of cancer. The increase and change in the levels of the tumor marker can be used primarily in the monitoring of the treatment of confirmed tumor patients and in the follow-up of the possible clinical progression of the tumor. The test package examines tumor markers that are more likely to affect women. Our package contains the following tests for the most basic tumor markers, in which case the increased levels may raise the suspicion of changes in the liver, colon, pancreas, ovary, breast, lungs: AFP (liver, ovarian cancer), LDH (melanoma), CEA (tumors of colon, rectum, stomach, liver, pancreas, lung, breast, ovary), CA 125 (tumors of ovary, endometrium, pancreas, liver), HE4 (ovary, lung cancer), NSE (lung, pancreas, thyroid tumors, neuroblastoma), ROMA index (ovarian cancer). A positive value does not necessarily mean cancer, but in this case, see your doctor to find out the reason for the increase in the marker level. A negative result does not completely rule out the presence of a tumor. The evaluation of the results and the establishment of a diagnosis are the responsibility of your treating physician.

LDH, AFP, CEA, CA 125, HE4, NSE, ROMA-index

The Basic tumor marker test package for women examines tumor markers that may indicate cancer that occurs primarily in women. Examining tumor marker levels is recommended mainly for monitoring the treatment of confirmed tumor patients and for following up the possible clinical progression of the tumor, but an abnormal level calls attention to a more thorough investigation. In case of deviation in marker concentrations, it is recommended to monitor the markers every one to two months.